Targeting Vascular Endothelial Growth Factor (VEGF) for Anti-tumor Therapy, by Anti-VEGF Neutralizing Monoclonal Antibodies or by VEGF Receptor Tyrosine-kinase Inhibitors

Author： Schlaeppi J-M.  

Publisher： Springer Publishing Company

ISSN： 0167-7659

Source： Cancer and Metastasis Reviews, Vol.18, Iss.4, 1999-12, pp. : 473-481

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti-VEGF and Anti-EGFR Monoclonal Antibodies in the First-line Therapy for Metastatic Colorectal Cancer - A Meta-Analysis

By  

Current Cancer Therapy Reviews, Vol. 7, Iss. 4, 2011-11 ,pp. : 282-289

Bentham Science Publishers

Access to resources Recommend Favorite

Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy

By Witte L.  

Cancer and Metastasis Reviews, Vol. 17, Iss. 2, 1998-06 ,pp. : 155-161

Springer Publishing Company

Access to resources Recommend Favorite

Mechanisms of Drug Resistance to Vascular Endothelial Growth Factor (VEGF) Inhibitors

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 10, Iss. 8, 2010-10 ,pp. : 593-600

Bentham Science Publishers

Access to resources Recommend Favorite

Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma

By Lu Kan V   Bergers Gabriele  

CNS Oncology, Vol. 2, Iss. 1, 2013-01 ,pp. : 49-65

Future Medicine

Access to resources Recommend Favorite

Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Inhibitors as Anti-Angiogenic Agents in Cancer Therapy

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 2, Iss. 1, 2007-01 ,pp. : 59-71

Bentham Science Publishers

Access to resources Recommend Favorite